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Abstract Global burden of diabetes mellitus clearly dem-
onstrate inadequacy of current diabetes care measures: the
costs of caring for patients with diabetes mellitus are the
highest compared to other frequent pathologies. Nonethe-
less, for every 10 s one patient dies of diabetes-related
consequences. Thus, there is urgent need for highly effective
measures that would lead to reduced prevalence, better long-
term outcomes and improved quality of life for diabetic
patients reducing associated economic burden. Such targeted
measures would require the creation of new guidelines for
advanced diabetes care that would provide for regulation, for
timely predictive diagnostics as well as an effective
prevention and creation of individualized treatment algo-
rithms. Effective communication among the research com-
munity healthcare providers, policy-makers, educators and
organized patient groups (Federations of Diabetics) is of
paramount importance and essential for (pre)diabetes care.
The ultimate mission of the “European Association for
Predictive, Preventive & Personalised Medicine” is to
promote this process in Europe and across the globe.
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Predictive diagnostics as the platform for personalized
medicine: new philosophy & strategic trends
in healthcare
Predictive, preventive & personalized medicine is a new
philosophy in healthcare aimed at application of innovative
biotechnologies in the prediction of human pathologies, the
development of timely prevention and individualized
therapy-planning. The advantages of predictive diagnostics
and personalized treatment include prevention of the
majority of disorders, personalized treatment, individual
therapy planning, substantial improvement of life-quality,
plausible solutions for particular social and ethical and
serious economical problems that we face in the current
healthcare system. This kind of progress can be achieved by
highly professional application of currently available
biotechnological approaches focused on solving the accu-
mulating problems in healthcare.
Predictive diagnostics is considered as a reliable navi-
gation system for targeted preventive measures and conse-
quent development of individualized treatment approaches.
Of paramount importance is communication among pro-
fessionals—medical doctors, biotechnologists, computer-
scientists, healthcare providers, policy-makers, educators,
who are obligatorily involved in the paradigm change from
curative (interventional) to predictive medicine. This
concept is considered as medicine of future. The paradigm
change can be achieved only by well-coordinated fulfillment
of the following components:
– adequate investment creating novel technologies
– development of non- orminimally-invasive diagnostic tools
– well-organized process for exchange and transfer of
knowledge among biomedical research entities and
biotechnological industries for production of the ad-
vanced diagnostic tools
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– quality assurance through the introduction of interna-
tional standards for technological tools and devices,
patenting and licenses
– appropriate professional education in terms of the
application of high-tech biotechnology in medicine
– effective regulations in the healthcare sector: introduc-
tion of the obligatory guidelines and clear regulations
for the health insurance industry to ensure patients
needs are met
– measures to ensure confidentiality of patient informa-
tion and personal databank
– distribution of relevant information among healthcare
professionals and users.
The overall concept of the paradigm change to predictive
and personalized medicine has been recently presented in
the worldwide pioneer book worked out by 60 leading
experts from 16 countries [1]. The coordinated measures,
described above, should be well-focused on solving the
accumulating problems in healthcare and the concomitant
economical burden that societies are increasingly faced
with across the globe.
The mission of the European Coordinator in this field
is performed by the “European Association
for Predictive, Preventive and Personalised
Medicine”
The concepts of innovative European and international
projects, which EPMA represents for further consideration
at the EU-Commission, the European Parliament, WHO
and UNO (see Fig. 1) are worked out by the consortium of
the world-leading professionals (Europe-unrestricted).
The first meeting of the EPMA-Representatives with the
Vice-Secretary General of UNO took place in Geneva on
December 8th 2009. The EPMA-Mission and-Objectives in
the field of Predictive, Preventive & Personalized Medicine
(PPPM) have been introduced to the Vice-Secretary
General of UNO. The participants of the meeting agreed
that the paradigm change from curative to PPPM can be
achieved only by coordinated measures well-focused on
solving the accumulating problems in healthcare and the
concomitant economical burden that societies across the
globe are facing more and more. This is a new philosophy
in healthcare and the platform for personalized patient’s
treatment considered as medicine of future.
Practical application of innovative technologies in favor
of predictive diagnostics, targeted preventive measures and
personalized patient treatment in European healthcare is the
central idea of the Association. By the international EPMA-
Journal, the Association welcomes a professional forum to
discuss most effective technologies and innovative
approaches of predictive, preventive and personalized
medicine.
Advanced (pre)diabetes care as the best model
for timely prediction, prevention and personalized
treatment
In terms of the urgent necessity for paradigm change from
interventional measures to predictive, preventive & person-
alized medicine, one of the best examples is healthcare of
permanently growing cohort of diabetic patients, which
represents a serious economical problem in most industri-
alized countries and countries with large populations.
Diabetes mellitus (DM) frequently results in diverse severe
complications, such as retinopathy, nephropathy, silent
ischemia, dementia, and cancer. Diabetes care faces a
whole spectrum of problems including the necessity for
population screening, targeted preventive measures, ethics,
economics, and broad dissemination of the issue-related
information that still await a dramatic improvement in
each aspect. As recently reviewed [2], at this stage we
recognize:
– the epidemic scale of the disease,
– the contemporary onset of the dominant diabetes type 2
in youth or even in childhood, and
Fig. 1 EPMA goes global in consensus with United Nations. From left
to right: EPMA-President—Vincenzo Costigliola, UNO-Vice-Secretary
General—Sergej Ordzhonikidze, EPMA-Secretary General—Olga
Golubnitschaja
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– a permanently growing number of well-acknowledged
severe complications of diabetes mellitus
Diabetes mellitus type 2, historically characterized as an
adult-onset disorder, now comprises approximately one
third of new DM-cases of those already in their second
decade of life [3]. Imbalanced nutrition and widespread
“fast food” consumption as well as irregular and low
physical activity in childhood contribute to the increasing
prevalence of obesity in youth. Consequently, the mean age
at diagnosis of DM type 2 in young population is 12–
14 years as reviewed by Huang & Goran [4].
Despite the current progress in individualized insulin
therapy, the common onset of DM type 2 in early adulthood
results in dramatic consequences that are linked to the early
onset of diverse severe complications such as retinopathy,
nephropathy, silent ischemia, and dementia. Chronic de-
generative processes affecting vital organs are well-
acknowledged as secondary DM complications. They
usually appear as a “domino-effect” in the characteristic
sequence as reviewed earlier [5]. Proliferative diabetic
retinopathy is attracting much attention being considered
as an early indicator of individual predisposition to the
cascade of chronic complications responsible for the
majority of morbidity and mortality in diabetics.
The recent years have brought new knowledge
concerning the predisposition to cancer in diabetic patients:
large population studies indicate an increased risk of liver,
pancreas, bladder, digestive and urinary tracts, and endo-
metrial cancer in DM with some ethnic and age-specific
differences as well as gender-dependent preferences [6, 7].
Although the molecular pathomechanisms of secondary
diabetic complications require further investigations,
emerging research has contributed well to our understand-
ing of the pathology in its whole complexity. Extensive
damage to DNA is well documented for cells isolated from
DM-patients [8] and can be well explained by impaired
glucose/insulin metabolism. These findings indicate an
imbalance between the increased production of ROS and
decreased DNA-repair capacity in diabetics. As long as
damaged cells can be repaired, the integrity of a
corresponding cell population remains intact. However, as
soon as a critical number of cells have damaged, two
potentially dangerous processes may be triggered in
affected organs: depending on the quality of cell-cycle
controlling machinery. This imbalance can lead either to
extensive apoptotic cell loss or proliferation of damaged
cells. Whereas the first process mainly causes tissue-
degeneration, the latter predisposes to pre-cancerous lesions
and tumor development. Both (neuro)degenerative alter-
ations in damaged organs and predisposition to cancer are
well documented in diabetes mellitus [9]. At early stages,
those alterations can be monitored by advanced analytical
technologies and used as a navigator for targeted preventive
measures in the group at high risk.
Given the high risk and prevalence of secondary
complications as well as individual predisposition to target
organ injury, DM is the best model for the application of
predictive diagnostics aimed at preventive measures and
personalized treatment. Generally, there are three levels
desirable for pre- and diabetes care [2]:
– 1st level: prediction of the predisposition early in
childhood
– 2nd level: prediction of early/premature aging and pre-
stages of diabetes
– 3rd level: prediction of diabetes-related complications.
First level—general predisposition to diabetes: postnatal
diagnostics, preventive measures early in life,
personalized treatment, and education
There is a growing body of evidence demonstrating certain
endogenous and exogenous factors to be strong contributors
to the prevalence of DM worldwide. Thus, the influence of
economic aspects with the respect to a higher DM-prevalence
in developing countries is evident [6, 10]. Further, current
population studies in perinatal and postnatal diagnostics
clearly show that developing countries have the highest
numbers of newborns affected by birth asphyxia—the most
frequent cause of mortality in children under 5 years of age
as well as of short- and long-term complications worldwide
[11]. It is noteworthy that the educational level of parents
correlates inversely with high risk and incidence of asphyctic
babies born across the population.
What is the link between diabetes and the most frequent
perinatal pathology—birth asphyxia? Molecular biological
analysis performed with animal models of perinatal asphyxia
provides clear evidence for a high predisposition of asphyctic
newborns to severe long-term outcomes such as diabetes
mellitus, neurodegenerative, cardiovascular and cancer dis-
eases [12]. Further diabetogenic effects have been demon-
strated for (a)typical antipsychotics (e.g. methylphenidate—
inhibitor of serotonin-reuptake) which are frequently pre-
scribed to treat attention-deficit / hyperactivity disorder
(ADHD) in children and youth [13, 14]. This disorder is
one of the long-term outcomes of birth asphyxia. In
particular cases, new onset of DM type 2 was observed
within first few days under ADHS-treatment with the (a)
typical antipsychotics [15, 16].
How can this knowledge be used in favor of targeted
preventive measures? Parents should be educated about the
risk factors and potential long-term outcomes, in order to
possibly prevent asphyxia. In the case of the asphyxiated
newborn, complementary postnatal diagnostic approaches
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should be applied to estimate the degree of the organ-
damage and potential long-term outcomes. Promising non-
invasive blood-tests are currently under development which
would allow a more precise diagnosis and reliable
prognosis for severe pathologies (diabetes, cancer, etc.),
which can be potentially developed later in life [12].
Further educational measures should consider well-known
pathology-relevant exogenous and endogenous factors such
as environmental aspects, genetic background, nutrition,
life style, stress, infections, job- and physical-activities [10,
17–19]. Some of the central factors and consequent recom-
mendations have been recently reviewed [2]. Physicians
should be well-educated for medication with antipsy-
chotics: it is advised to be cautious with the prescription
of diabetogenic agents [15]. Particular care is required
when treating ADHD in childhood and youth: special
attention should be paid to high-risk patients predisposed to
onset of DM. Monitoring of DM-relevant parameters (such
as dynamic of body-mass-index and blood-glucose levels)
is advised for careful set-up of individualized treatment
approaches.
Second level: Adulthood and pre-stages of Diabetes
mellitus
Aging is one of the strongest contributors to the develop-
ment of the majority of human pathologies including DM.
In particular, early or even premature aging is especially of
concern, since this supports or even triggers the (pre)
lesions, pre-stages and the consequent pathologies early in
life. Early aging can have diverse origins and usually
results from the interaction of genetic, epigenetic and
various environmental factors. The well-known causes of
the early/premature aging are inborn genetic disorders, such
as Down Syndrome, deregulation of longevity-associated
genes, disconnected functional interaction between nuclear
and mitochondrial genomes, environmental factors and
inappropriate reaction towards any kind of stress. The
common resulting effect is an imbalance in the production
of aggressive reactive species, amounts of antioxidants and
the activity of detoxification pathways that altogether
support extensive organ-damage [20].
The activity of detoxification pathways consistently
decreases for everybody during life. However, this
activity-fall is highly individual and can be estimated non-
invasively by non-sophisticated in vitro tests measuring the
induction of SOD-activity towards stress-conditions trig-
gered, e.g. by the in vitro application of paraquat to
leukocytes. The results of the test support well the key-
role of early aging in the manifestation of major pathologies
such as DM type 2 [21]. As reviewed earlier [2] the most
important message considering the targeted preventive
measures against early aging and manifestation of diabetic
pre-stages is the following:
1. Individuals within the 5th, 6th and 7th life-decades
demonstrate the biggest diversity in the induction of the
stress-reaction. These are the groups of particular
interest for examination and targeted prevention of
early aging.
2. Some individuals in the 6th decade of life exhibit
parameters similar to those in the 4th and even 3rd
ones; others, however, tend to show parameters more
characteristic for the 9th and 10th decades of life. The
latter are at high risk for aging-related pathologies. For
specific predispositions should be looked by predictive
diagnostic tools.
3. The individuals in the 10th decade of life demonstrate
better values compared to the majority in the 8th
decade. This group may provide us with new knowl-
edge about particularities of metabolism well protected
against aging.
An application of tests aimed at prediction of accelerated
aging is not expensive but very useful for the prediction of
aging-related pathologies such as diabetes mellitus.
Recent innovative diabetes-related studies offer a more
precise definition of the diabetic phenotype at the molecular
level that may prove useful in delineating diabetogenic
genes or gene products in diabetes pre-stages: an identifi-
cation of secreted and pancreas specific proteins/peptides
responsible for abnormalities of insulin secretion in type 2
DM and which might serve as predictive markers for β-cell
dysfunction in diabetes pre-stages was performed [22]. The
analysis resulted in the identification of 102 secreted
proteins which can be divided into five classes: (a) hormones
and related molecules, (b) protease inhibitors, (c) secretory
vesicle proteins, (d) cell adhesion or extracellular matrix
proteins, and (e) secreted enzymes. From all identified
secreted proteins only pancreatic polypeptide Y (PPY) was
identified as pancreas specific thereby, fulfilling the criterion
of a predictive marker. Further strategies for the detection
and identification of additional pancreas specific bio-
markers and characteristics for deficiency in insulin
secretion are necessary. Since one ideal biomarker is
difficult to find or may even not exist at all, a potential
solution might be to use the combinatorial power of
several biomarkers, each of which alone may not offer
satisfactory specificity and sensitivity. The creation of
individualized care algorithms is closely linked to the
identification of a set of molecular-targets that would
serve as the basis for the early diagnosis of pre-diabetes,
therapy selection and disease monitoring that together
could lead to personalized treatment options [23].
Currently, for individuals highly predisposed to the early
aging / extensive aging-processes generally and, in particular
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to diabetes pre-stages, the following preventive and thera-
peutic measures are recommended:
– The life-style should be personally discussed with the
specialists to develop individualized nutrition and
optimized physical and further activity taking into
account all related stress contributors including the
relevant environmental factors [24];
– Targeted metabolic corrections might be performed [5];
– Gene-therapy and alternative forms of individualized
therapy approaches can be potentially applied [25].
Third level: Prediction and personalized treatment
approaches slowing down or even preventing severe
complications secondary to diabetes
Chronic vasodegenerative disease as early manifestation
of the complication-cascade
In addition to the aging processes, there is the likelihood of
extensive damage to numerous organs in diabetes. Severe
complications that develop secondarily to DM represent the
main cause of morbidity and mortality among diabetic
patients. According to the current worldwide statistics, DM
is currently the fourth leading cause of death [26], in
particular, due to fatal DM-related complications [27]. Since
our knowledge concerning all DM-triggered secondary
pathologies is currently incomplete, the real figures for
DM-related mortality are assumed to be significantly higher
than considered till now. The common onset of DM type 2 in
early adulthood leads to dramatic consequences linked with
the early onset of diverse severe complications such as
retinopathy, nephropathy, silent ischemia, dementia and
“diabetic foot”. Chronic degenerative processes affecting
vital organs are well acknowledged in DM; they usually
appear as a “domino-effect” in the characteristic sequence
reviewed earlier [5]. An active proliferative diabetic retinop-
athy is considered to be an early indicator of an individual
predisposition to the cascade of severe chronic complications
that usually develop down-stream towards the manifestation
of DRP. Therefore, early/predictive diagnosis of DRP is a
reasonable indication for immediate preventive measures and
individualized therapy [28]. Diabetic angiopathy involving
the small capillary vessels and intra-retinal fluid collection in
macula can be the earliest signs of DM, even before the
diagnosis of an “active” disease. Consequently, the retinal
screening in the risk subpopulations makes good sense to be
performed, before other manifestations are noted. Moreover,
the early ischemic alterations in the retina can predict the
prognosis and even the severity of possible systemic
complications to be expected. Retinal ischemic changes
detected by Fluorescein Angiography are the reliable
indicator for systemic ischemic changes followed by blood
flow disturbances leading to ischemic brain and diabetic foot.
Diabetic Poly-Neuropathy (DPN)
Since the topic “Predictive, Preventive & Personalized
Medicine in treatment of Neurodegenerative Diseases” will
be regularly discussed in the special issue of the EPMA-
journal, here we provide only a brief overview of important
aspects of DPN:
➢ DPN is the most common form of peripheral
neuropathy accompanied by sensory loss, visual loss,
compromised pain sensation and brain atrophy [29–31].
➢ Retinopathy is developed by 30–50% of diabetic
patients [28].
➢ Extremely high co-morbidity is observed for patients
with sight-threatening diabetic retinopathy [32].
➢ Early retinopathy is the reliable indicator of severe
diabetic complications upstream of the cascade of
degenerative processes in other organs. Consequently,
proliferative diabetic retinopathy is frequently accompa-
nied by diabetic maculopathy, angina, painless cardiac
infarction, stroke, renal disease, foot ulceration [33–36].
➢ Following relevance of DPN is considered for the
major neurodegenerative pathologies:
– Both DM type 1 and Multiple Sclerosis are
autoimmune disorders with etiological similar-
ities [37].
– The common feature of DM and Parkinson’s
Disease is the mitochondrial dysfunction [38, 39].
– DM is of limited relevance for the development
of Alzheimer Disease, which is considered as
Diabetes type 3 due to insulin resistance in
particular organ—the brain [40–42].
– Diabetes is considered of no special risk for
glaucoma pathology [43].
Cancer predisposition in Diabetes: contributing factors
and indicators to predict the pathology
The recent years have brought new knowledge concerning the
predisposition to cancer in diabetic patients: the large popula-
tion studies performed indicate an increased risk for and mor-
tality related to liver, pancreas, bladder, kidney, colon, stomach,
rectum, endometrium, ovarian, and cervix cancer types in DM
with some ethnic and age-specific differences as well as
gender-dependent preferences [6, 7]. The etiology of cancer in
DM remains elusive. However, it is evident that multiple
factors contribute to cancer in DM including the following:
– Major stress factors (excessive metabolic alterations,
disturbed glucose/insulin homeostasis, hormonal deregu-
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lation, insufficient detoxification) with consequent exces-
sive production of ROS.
– Mitochondrial dysfunction with consequent low energy
production and insufficient repair capacity, accumulat-
ing damage to both mitochondrial and chromosomal
DNA.
– High risk for infectious disorders with consequently
induced viral pro-oncogenic activity as well as activity
of particular pathogenic bacterial forms such as
Helicobacter pylori.
Cancer predisposition in Diabetes is reviewed in this
journal-issue [44].
Advanced diagnostic approaches for prediction
of secondary diabetic complications
A prime target of hyperglycemia-induced injury is the
endothelial cells, the damage of which contributes to the
macro- and microvascular complications. Consequently,
cardiovascular diseases are the leading cause of death in
diabetic patients, accounting for about 65 % of the deaths
among patients with type 2 diabetes mellitus; much of the
morbidity and mortality relates to atherosclerotic coronary
artery disease, congestive heart failure and sudden cardiac
arrest [35]. A further significant portion of diabetic patients
develop cancer or neurodegenerative diseases as described
in the above subchapters. Importantly, however, not all
diabetic patients experience severe long-term complications
irrespective of blood glucose control. For example, about
20–40 % of diabetic patients ultimately develop a nephrop-
athy but it is not clear why all diabetic patients do not
manifest this complication. Nonetheless, differential sus-
ceptibility to chronic diabetic complications indicates that,
aside from hyperglycemia, other factors (e.g. genetics)
modulate an individual’s risk for vascular complications.
These aspects emphasize the need for an individualized
approach to detection and management of diabetes mellitus.
As a result, identification of effective diagnostic markers
and prognostic indicators unique to diabetes mellitus should
prove valuable for early diagnosis and targeted preventive
or individualized interventional measures.
Although urinary proteomics is considered as a poten-
tially powerful diagnostic tool for the early detection of
diabetic renal damage, major limitations of the technology
should be addressed. From a technical viewpoint, the
analysis of low level proteins is the major limitation.
Therefore, gel-free analytical systems combined with pre-
fractionation prior to analysis are required to solve this
technical problem. Further, the examination should be very
well designed, particularly in terms of sample collection.
Thus, peptide patterns for first-void and mid-stream female
urine are different, i.e. a contamination from non-urinary
passage is an obvious obstacle, particularly for analyses
conducted with female subgroups [45]. Finally, data
achieved by urinary proteomics are complicated due to
their correct interpretation currently giving rise to many
unanswered questions. Since disease specific changes in
blood-plasma and vascular proteomes occur up-stream
towards the majority of organ systems in type 2 diabetes
[46], it should be clarified as to which changes monitored
in the renal proteome originate from the kidney and which
from other organs. Therefore, the current challenge is
whether predictive indications for developing secondary
diabetic complications, including nephropathy, should be
sought in plasma rather than in urinary proteomics [5]. A
detection of pathology-specific circulating nucleic acids in
blood-plasma is considered as one of the most potent
diagnostic approaches in the individualized treatment of
diabetic patients [47, 48]. Thus, reliable prediction of
endothelial dysfunction in diabetes basing on circulating
markers [49] and prognostic targets specifically for diabetic
retinopathy basing on detection of oxidative-stress and
apoptotic metabolites in blood is proposed in this journal-
issue [50].
A non-invasive molecular diagnostic approach based on
disease-specific gene expression patterns in circulating
leukocytes has been recently suggested for the predictive
diagnosis of secondary diabetic complications [51]. This
approach is based on disease-and severity-specific alter-
ations in the gene expression patterns of circulating
leukocytes and protease activity in serum that can be ex
vivo evaluated in individual blood samples. The test
foresees a precise expression profiling of selected genes in
circulating leukocytes isolated from fresh blood samples.
These genes, which have been proposed to play a role in
the pathology of type 2 diabetes, belong to the stress-
proteome and have a function in the following pathways:
cell-cell communication, cell-adhesion, apoptosis, tumori-
genesis, transcription regulation, tissue remodeling and
neurodegeneration. A clinical application of the test is
currently under consideration, and a nanotechnology which
should provide a possible easy and relatively inexpensive
routine application of the test is under development [52].
Creation of individualized therapy approaches
In light of the above, an early and predictive diagnosis
followed by targeted preventive measures and individual-
ized therapy approaches would dramatically improve the
overall outcome of secondary complications in diabetic
patients. An excellent example can be given by advanced
ophthalmo-diabetological care for individualized patient
treatment, e.g. when therapeutic approaches such as
vitrectomy are applied [53, 54]. The technique of vitrecto-
my is rapidly improving and clinical guidelines should take
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its progress into consideration. Novel techniques of intra-
vitreal drug application show some positive effects.
However, there is a lack of randomized, well-controlled
trials that can potentially result in improved guidelines for
clinical practice. Severe and moderate vision loss in
diabetes mellitus is essentially preventable by advanced
early and predictive diagnostics and personalized patients
treatment. Advanced treatment approaches are possible
only by understanding the molecular and pathophysiolog-
ical mechanisms of the disease and precise prediction of
individual complications. The interplay between three
vasoactive systems, VEGF, prostaglandins and NO, have
predictive power in the progression of the ischemic retinal
changes [39]. As for the individual treatment, the goal of
the personalized vitrectomy is accomplished with the
modern drug usage such as anti-VEGF therapeutic
approaches, the algorithms for which can be personally
modeled depending on the kind and stage of diabetic
retinopathy. Further, advanced reparative cell-therapy
approaches have been suggested to treat vasodegenerative
disease in the retina [55].
A further example can be given for the prediction and
individualized treatment of aortic valve degeneration and
replacement in diabetic patients. On average, 20–30 % of
implanted bioprostheses show dysfunction after about
10 years post implantation. Recent reports predict that a
greater than 50 % incidence of failure will be seen in
bioprostheses at 12–15 years [56]. These figures are much
worse for diabetic patients, who are at high risk for
degeneration of both native valvular tissue and bioprostheses
[20]. To predict the progressive valvular degeneration and
necessity of accelerated re-implantation, comparative expres-
sion analyses have been undertaken demonstrating the high
predictive power of some marker-candidates and novel
therapeutic targets [57, 58]. Among them—the ECM-
degrading enzymatic-core, the expression profile of which
changes dramatically at the remodeling of valvular geometry
and complications such as accelerated degeneration of bio-
prostheses [36, 58]. Moreover, the activity of the tissue-
remodeling key-enzymes-metalloproteinases MMP-2 and
MMP-9—can be non-invasively measured in blood by ex
vivo zymography [5]. Individual stress response, quality of
cell-cycle control, and imbalance in tissue-remodeling
protein-complexes may play a pivotal role in severity of
degenerative processes. This opens good perspectives for
predictive diagnostics, new targets and individualized ther-
apy approaches for diabetic patients [59].
Further, intense research is currently devoted to the
detection of pathology-specific molecular pathways for
consequent development of improved diagnostic and
therapeutic targets: the potential role of Indoleamine-2,3-
Dioxygenase-dependent molecular pathway as an effective
predictive and therapeutic target in diabetes diagnostics and
treatment is demonstrated in this journal-issue [60]. For
early detection of diabetic nephropathy and consequent
monitoring of pathology-progression under individually
created treatment algorithms, specifically inflammatory
cytokines can be chosen for development of advanced
prognostic tools as reviewed by Elmarakby et al [61].
Advanced drug delivery systems present indubitable
advances for organ-selective and targeted treatment of
diabetes and secondary pathologies. Minimally invasive
Fig. 2 The overall EPMA-
concept of the communication
and output among field-related
researchers, healthcare pro-
viders, policy-makers, educators
and organized patient groups
(e.g. Federations of Diabetics)
that are intimately involved in
(pre)diabetes care
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insulin administration approaches and / or improvement of
pancreatic insulin secretion is the main goal of novel drug
delivery systems and is highly desirable for advanced
treatment of diabetic patients with both type 1 and type 2
[62–65].
Noteworthy, using individualized treatment algorithms
based on well-established conventional methodology, such
as optimized surgical timing in treatment ocular diabetic
complications, post-interventional recovery, long-term out-
comes and life-quality of treated diabetics can be dramat-
ically improved as reported in this issue [66, 67].
Surprisingly, the highly relevant topic of periodontitis
risk in diabetic subpopulation is rarely discussed in context
of advanced diabetes care. Current journal-issue promotes
this discussion with a contribution from the experts in the
field [68].
Conclusions & outlook
– Global figures clearly demonstrate inadequacies of
current diabetes care: actual economical burden are
the highest for diabetes care compared to all other
frequent pathologies.
– Yet, every 10 s one patient dies of diabetes-related
consequences.
– Due to epidemic scale of the pathology, severe
complications and extremely high co-morbidity, current
diabetes care requires urgent and highly effective
measures that would lead to reduced prevalence of
diabetic complications, better long-term outcomes and
life quality of patients as well as reducing the growing
economic burden.
– These targeted measures require the creation of new
guidelines for advanced diabetes care which would
provide for proper regulation of timely predictive
diagnostics, an effective prevention and creation of
individualized treatment algorithms.
– Communication among scientists, healthcare-providers,
policy-makers, educators and organized patient groups
(e.g. Federations of Diabetics) intimately involved in (pre)
diabetes care is of paramount importance (see Fig. 2).
– Global organizations involved in the process should be
well networked in the topic in order to promote this
important mission.
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